Reflections upon human cancer immune responsiveness to T cell-based therapy

Ena Wang, Sara Tomei, Francesco M. Marincola

Research output: Contribution to journalComment/debate

7 Citations (Scopus)

Abstract

Immune-mediated rejection of human cancer is a relatively rare but well-documented phenomenon. Its rate of occurrence progressively increases from the occasional observation of spontaneous regressions to the high rate of complete remissions observed in response to effective treatments. For two decades, our group has focused its interest in understanding this phenomenon by studying humans following an inductive approach. Sticking to a sequential logic, we dissected the phenomenon by studying to the best of our capability both peripheral and tumor samples and reached the conclusion that immune-mediated cancer rejection is a facet of autoimmunity where the target tissue is the cancer itself. As we are currently defining the strategy to effectively identify the mechanisms leading in individual patients to rejection of their own tumors, we considered useful to summarize the thought process that guided us to our own interpretation of the mechanisms of immune responsiveness.

Original languageEnglish
Pages (from-to)761-770
Number of pages10
JournalCancer Immunology, Immunotherapy
Volume61
Issue number6
DOIs
Publication statusPublished - Jun 2012
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
T-Lymphocytes
Neoplasms
Autoimmunity
Observation
Therapeutics

Keywords

  • Cancer vaccines
  • CIMT 2011
  • Immunoresponsiveness
  • Melanoma
  • Tumor immunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Reflections upon human cancer immune responsiveness to T cell-based therapy. / Wang, Ena; Tomei, Sara; Marincola, Francesco M.

In: Cancer Immunology, Immunotherapy, Vol. 61, No. 6, 06.2012, p. 761-770.

Research output: Contribution to journalComment/debate

@article{7da39a0c35ad4ede9b5063f8535f90b4,
title = "Reflections upon human cancer immune responsiveness to T cell-based therapy",
abstract = "Immune-mediated rejection of human cancer is a relatively rare but well-documented phenomenon. Its rate of occurrence progressively increases from the occasional observation of spontaneous regressions to the high rate of complete remissions observed in response to effective treatments. For two decades, our group has focused its interest in understanding this phenomenon by studying humans following an inductive approach. Sticking to a sequential logic, we dissected the phenomenon by studying to the best of our capability both peripheral and tumor samples and reached the conclusion that immune-mediated cancer rejection is a facet of autoimmunity where the target tissue is the cancer itself. As we are currently defining the strategy to effectively identify the mechanisms leading in individual patients to rejection of their own tumors, we considered useful to summarize the thought process that guided us to our own interpretation of the mechanisms of immune responsiveness.",
keywords = "Cancer vaccines, CIMT 2011, Immunoresponsiveness, Melanoma, Tumor immunotherapy",
author = "Ena Wang and Sara Tomei and Marincola, {Francesco M.}",
year = "2012",
month = "6",
doi = "10.1007/s00262-012-1274-9",
language = "English",
volume = "61",
pages = "761--770",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",

}

TY - JOUR

T1 - Reflections upon human cancer immune responsiveness to T cell-based therapy

AU - Wang, Ena

AU - Tomei, Sara

AU - Marincola, Francesco M.

PY - 2012/6

Y1 - 2012/6

N2 - Immune-mediated rejection of human cancer is a relatively rare but well-documented phenomenon. Its rate of occurrence progressively increases from the occasional observation of spontaneous regressions to the high rate of complete remissions observed in response to effective treatments. For two decades, our group has focused its interest in understanding this phenomenon by studying humans following an inductive approach. Sticking to a sequential logic, we dissected the phenomenon by studying to the best of our capability both peripheral and tumor samples and reached the conclusion that immune-mediated cancer rejection is a facet of autoimmunity where the target tissue is the cancer itself. As we are currently defining the strategy to effectively identify the mechanisms leading in individual patients to rejection of their own tumors, we considered useful to summarize the thought process that guided us to our own interpretation of the mechanisms of immune responsiveness.

AB - Immune-mediated rejection of human cancer is a relatively rare but well-documented phenomenon. Its rate of occurrence progressively increases from the occasional observation of spontaneous regressions to the high rate of complete remissions observed in response to effective treatments. For two decades, our group has focused its interest in understanding this phenomenon by studying humans following an inductive approach. Sticking to a sequential logic, we dissected the phenomenon by studying to the best of our capability both peripheral and tumor samples and reached the conclusion that immune-mediated cancer rejection is a facet of autoimmunity where the target tissue is the cancer itself. As we are currently defining the strategy to effectively identify the mechanisms leading in individual patients to rejection of their own tumors, we considered useful to summarize the thought process that guided us to our own interpretation of the mechanisms of immune responsiveness.

KW - Cancer vaccines

KW - CIMT 2011

KW - Immunoresponsiveness

KW - Melanoma

KW - Tumor immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84862326540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862326540&partnerID=8YFLogxK

U2 - 10.1007/s00262-012-1274-9

DO - 10.1007/s00262-012-1274-9

M3 - Comment/debate

VL - 61

SP - 761

EP - 770

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 6

ER -